Extraordinary general meeting of the shareholders in Biacore

Extraordinary general meeting of the shareholders in Biacore The shareholders in Biacore International AB (SSE: BCOR; Nasdaq: BCOR) are invited to an Extraordinary General Meeting on Monday, August 28, 2000. The purpose of the meeting will be to decide whether Biacore International AB (the Company) should issue subordinated notes at a nominal value of maximum SEK 100,000 with 380,000 attached warrants for subscription to new shares in the Company. Should the warrants be fully utilized, the Company's share capital will increase by a maximum of SEK 3,800,000. This increase corresponds to a dilution of the current share capital by approximately 3.8 percent. The subordinated notes will, with an exception to the preferential rights of the shareholders, be fully subscribed by a wholly owned subsidiary of the Company. The reason the board wants to make this exception to the preferential rights of the shareholders is that it wants to further improve the Company's long-term financial development by offering current and future employees in the Biacore group a well considered incentive programme. This will make it possible for employees to benefit from a positive development of the Company's value. To the editors: Biacore is a global market leader in affinity-based biosensor technology with its own sales operations in the US, across Europe, in Japan, Australia and New Zealand. The technology is protected by a strong patent portfolio. Target groups consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies all over the world. Biacore focuses on drug discovery as the prime area for future growth. Based in Uppsala, Sweden, the company is listed on the OM Stockholm Exchange and Nasdaq in the US. In 1999 the company had sales of SEK 340.4 million and an operating income of SEK 67.6 million. Further information on Biacore can be found on the web at www.biacore.com. Address and phone: Biacore International AB Rapsgatan 7, SE-754 50 Uppsala, Sweden Phone: +46 (0) 18 67 57 00, Fax: +46 (0) 18 15 01 11 info@biacore.com Lars-Olov Forslund, CFO phone +46 (0) 18 67 57 08 Jan Isoz, Investor Relations phone +46 (0) 708103 117 ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/08/09/20000809BIT00520/bit0001.doc http://www.bit.se/bitonline/2000/08/09/20000809BIT00520/bit0002.pdf

About Us

Biacore™ systems for label-free interaction analysis generate unique data on molecular interactions, giving insights into biological functions and disease mechanisms, and facilitating efficient therapeutic development. Application areas include drug discovery, general life science research, antibody characterization, immunogenicity, biotherapeutic development and manufacture. Biacore AB is a GE Healthcare company. Further information: www.biacore.com